The El Escorial criteria: Strengths and weaknesses (Q57911703)

Orla Hardiman

4

0 references

Pamela Shaw

Pamela Shaw

8

0 references

Massimo Filippi

Massimo Filippi

3

0 references

Ammar Al-Chalabi

2

Ammar Al-Chalabi

0 references

Vincent Meininger

6

Vincent Meininger

0 references

Leonard H van den Berg

10

Leonard H. van den Berg

0 references

Albert C. Ludolph

11

Albert Ludolph

0 references

author name string

Ryuji Kaji

5

0 references

Imaharu Nakano

7

0 references

Jeremy Shefner

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

9

0 references

publication date

8 December 2014

0 references

published in

0 references

volume

16

0 references

issue

1-2

0 references

page(s)

1-7

0 references

cites work

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Factors affecting the diagnostic delay in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Proposed criteria for familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Early symptom progression rate is related to ALS outcome: a prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Natural history and clinical features of the flail arm and flail leg ALS variants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Neuroimaging in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

The cortical signature of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

MRI predictors of long-term evolution in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Cognitive dysfunction in lower motor neuron disease: executive and memory deficits in progressive muscular atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Genetic overlap between apparently sporadic motor neuron diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Sporadic lower motor neuron disease with adult onset: classification of subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

The risk to relatives of patients with sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Modelling the effects of penetrance and family size on rates of sporadic and familial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Exome sequencing reveals VCP mutations as a cause of familial ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Cognitive changes predict functional decline in ALS: a population-based longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Basal ganglia involvement in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Stages of pTDP-43 pathology in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Screening for cognition and behaviour changes in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258

Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.964258